Morning Overview on MSN
The first cellular age-reversal therapy has been cleared for human trials
Life Biosciences has received FDA clearance to begin a first-in-human Phase 1 clinical trial of ER-100, a gene therapy ...
Inherited retinal degenerations (IRDs) are a group of genetic disorders that lead to progressive vision loss as the light-sensing cells of the eye—the photoreceptors—die due to mutations in genes ...
A gene therapy that targets a form of retinitis pigmentosa showed a signal to improve retinal function for up to 3 years after treatment, according to a small clinical trial. The phase 2 SKYLINE trial ...
Khanani, MD, MA, FASRS, founded Clinical Trials at the Summit (CTS) 6 years ago, the vision was to bring all stakeholders in retinal drug development together under one roof. At this year's meeting, ...
Researchers from the NIHR Moorfields Biomedical Research Centre and University College London have found that gene therapy improved visual acuity and preserved retinal structure in young children with ...
Ocugen, Inc., a biotechnology company focused on gene therapies for blindness diseases, announced updates to its Retina Scientific Advisory Board and Executive Leadership Team. These changes are ...
An experimental MeiraGTx gene therapy that has clinical data showing reversal of blindness in children born with a rare, inherited eye disorder is heading to Eli Lilly. According to the terms of the ...
Hot on the heels of a $150 million fundraise, Atsena Therapeutics is back with early-stage data for the company’s eye disease gene therapy. The candidate improved the structure and function of the ...
Blind People Offered Hope of Seeing Again After Stem Cell Breakthrough Remakes Retinal Blood Vessels
When injected into mice with retinal disease, the special retinal blood cells integrated into the damaged tissue to ...
Prior clinical successes with gene therapy for one of these diseases has raised hopes for patients and families affected by other such diseases, " says Editor-in-Chief Terence R. Flotte, MD, Celia and ...
Ocugen, Inc., a biotechnology company focused on gene therapies for blindness diseases, announced its participation in two significant upcoming conferences: the ARVO 2025 Annual Meeting in Salt Lake ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results